A Novel Pyrazolopyridine with in Vivo Activity in Plasmodium berghei- and Plasmodium falciparum-Infected Mouse Models from Structure-Activity Relationship Studies around the Core of Recently Identified Antimalarial Imidazopyridazines

J Med Chem. 2015 Nov 12;58(21):8713-22. doi: 10.1021/acs.jmedchem.5b01605. Epub 2015 Nov 2.

Abstract

Toward improving pharmacokinetics, in vivo efficacy, and selectivity over hERG, structure-activity relationship studies around the central core of antimalarial imidazopyridazines were conducted. This study led to the identification of potent pyrazolopyridines, which showed good in vivo efficacy and pharmacokinetics profiles. The lead compounds also proved to be very potent in the parasite liver and gametocyte stages, which makes them of high interest.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antimalarials / chemistry*
  • Antimalarials / pharmacokinetics
  • Antimalarials / pharmacology
  • Antimalarials / therapeutic use*
  • Ether-A-Go-Go Potassium Channels / metabolism
  • Humans
  • Liver / parasitology
  • Malaria / drug therapy*
  • Malaria / parasitology
  • Malaria, Falciparum / drug therapy
  • Malaria, Falciparum / parasitology
  • Mice
  • Plasmodium berghei / drug effects*
  • Plasmodium falciparum / drug effects*
  • Pyrazoles / chemistry*
  • Pyrazoles / pharmacokinetics
  • Pyrazoles / pharmacology
  • Pyrazoles / therapeutic use*
  • Pyridines / chemistry*
  • Pyridines / pharmacokinetics
  • Pyridines / pharmacology
  • Pyridines / therapeutic use*
  • Rats
  • Structure-Activity Relationship

Substances

  • Antimalarials
  • Ether-A-Go-Go Potassium Channels
  • Pyrazoles
  • Pyridines
  • pyrazolopyridine